Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30163265 | 0.89 | MTNR1A (0.48) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL22802370 | 0.89 | MTNR1A (0.48) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL23692360 | 0.86 | NLRP3 (0.36) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL20681241 | 0.85 | MTNR1A (0.37) | MTNR1AMTNR1BGAASOAT2MYC | |
| SCHEMBL19508129 | 0.85 | PSEN1 (0.39) | MTNR1AMTNR1B | |
| SCHEMBL25067001 | 0.85 | MTNR1A (0.46) | MTNR1AMTNR1BNLRP3 | |
| SCHEMBL20681199 | 0.84 | GABRA1 (0.46) | MTNR1AMTNR1BGAASOAT2MYC | |
| SCHEMBL19507082 | 0.84 | GABRA1 (0.46) | MTNR1AMTNR1BGAASOAT2MYC | |
| SCHEMBL20681237 | 0.83 | MTNR1A (0.37) | MTNR1AMTNR1B | |
| SCHEMBL28411067 | 0.83 | THRA (0.40) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-01-30 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| EP-3658538-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-16 | — | — | US | disclosed |
| EP-3658538-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis Inflammasome Research, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| CN-111094242-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华炎症研究公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2019023145-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019023145-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079631-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MTNR1A 1586/4885MTNR1B 2060/4885NLRP3 2/4885 |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MTNR1A 1895/4885MTNR1B 2460/4885NLRP3 2/4885 |
| US-11884645-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, ABCC5 | MTNR1A 606/4885MTNR1B 946/4885NLRP3 1/4885 |
| US-11834433-B2 | Compounds | NLRP3, NOD1, PYCARD | MTNR1A 382/4885MTNR1B 708/4885NLRP3 1/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MTNR1A 1586/4885MTNR1B 2060/4885NLRP3 2/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | MTNR1A 272/4885MTNR1B 670/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.